Streetbeat News

Analyst Ratings

HR

Wedbush analyst Richard Anderson has reiterated an Outperform rating on Healthcare Realty Trust (NYSE:HR) and maintained a $17 price target.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 3:18 pm

PACB

Piper Sandler analyst David Westenberg has maintained a Neutral rating on Pacific Biosciences (NASDAQ:PACB) and lowered the price target from $9 to $8.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 3:16 pm

HUM

Humana's (NYSE:HUM) short percent of float has risen 20.3% since its last report, with 2.93 million shares sold short, which is 2.37% of all regular shares available for trading. It would take traders 2.8 days to cover their short positions on average. An increase in short interest can signal that investors have become more bearish. However, Humana's peer group average for short interest as a percentage of float is 2.99%, which means the company has less short interest than most of its peers.

Portfolio Pulse from Benzinga Insights

November 06, 2023 | 3:15 pm

A

Agilent Technologies's short percent of float has fallen 6.49% since its last report, with 3.74 million shares sold short, which is 1.44% of all regular shares available for trading. This decrease in short interest could signal a more bullish market sentiment towards the stock. Compared to its peers, Agilent has less short interest, with an average of 5.41% for its peer group.

Portfolio Pulse from Benzinga Insights

November 06, 2023 | 3:15 pm

LHX

L3Harris Technologies's (NYSE:LHX) short percent of float has fallen 3.23% since its last report, with 1.69 million shares sold short, which is 0.9% of all regular shares available for trading. This decrease in short interest could signal a more bullish sentiment towards the stock. However, it does not necessarily mean that the stock price will rise in the near term. Compared to its peers, L3Harris has less short interest.

Portfolio Pulse from Benzinga Insights

November 06, 2023 | 3:15 pm

DGX

Piper Sandler analyst David Westenberg maintains a Neutral rating on Quest Diagnostics (NYSE:DGX) and raises the price target from $130 to $140.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 3:14 pm

EVAX

Evaxion Biotech A/S (NASDAQ:EVAX) has shared the latest phase 2 clinical data for its lead clinical asset, EVX-01, in a webinar with key opinion leader Adnan Khattak. The data confirms the promising results of the phase 1 trial. The company believes that its AI-Immunology™ platform, which powers EVX-01, has the potential to revolutionize cancer treatment, particularly for malignant melanoma.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 3:13 pm

BIRK

Deutsche Bank analyst Gabriella Carbone initiates coverage on Birkenstock Holding (NYSE:BIRK) with a Hold rating and announces a price target of $43.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 3:11 pm

BIRK

William Blair analyst Sharon Zackfia has initiated coverage on Birkenstock Holding (NYSE:BIRK) with an Outperform rating.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 3:08 pm

ADNT

Zacks Surprise Trader has picked Adient (ADNT) as a stock to watch, according to recent reports.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 3:05 pm